K. Sean Kimbro is a professor of Biological and Biomedical Sciences at the North Carolina Central University, Durham, NC. Currently, he is the lead principal investigator (PI) on a National Institutes of Health Transformative R01, the first time this type of grant has been awarded to an HBCU.
Dr. Kimbro received his undergraduate from Washington University in St. Louis, Missouri, in 1987, and his Ph.D. in Molecular and Microbiology from Indiana University, Bloomington, Indiana, in 1993. From 1993 to April 1995, he was a postdoctoral fellow at Harvard Medical School and from 1995 to 1997 a postdoctoral fellow at the National Institutes of Health, National Institute of Environmental Health Sciences.
In 1997, Dr. Kimbro was an assistant professor at Clark Atlanta University, Department of Biological Sciences, in Atlanta, Georgia. In 2004, Dr. Kimbro was recruited to direct the NIH Center of Excellence, the Georgia Center for Health Equality at Winship Cancer Institute, Emory University. He was later recruited to North Carolina Central University to be the second director of the Julius L. Chambers Biomedical/Biotechnology Research Institute in 2010. In 2014, Dr. Kimbro received funding to continue his research in cancer health disparities and returned to the lab to study immunity and breast/prostate cancers, including type 2 diabetes and obesity.
Today, Dr. Kimbro trains multiple Ph.D. and master's students in his laboratory and is actively engaged in North Carolina's Halifax County addressing health disparities.
Dr. Kimbro's research interests include the molecular characterization of hormonal cancers, including prostate and breast cancer. He has additional interests in the characterization of those cancers that disproportionately affect various ethnic groups. More recently, he has ventured into epigenetic research, exploring the role of microRNAs in type 2 diabetes of African Americans. He has been influential in the continued efforts to increase the number of African-American and Hispanic American cancer researchers and the recipient of numerous awards from the American Association for Cancer Research. In addition to his success in the classroom, mentoring and leadership, he has generated over 10 million dollars in research over his career. Read more about Dr. Kimbro's research at his lab page.
Indiana University, Bloomington
Washington University in St. Louis
1. S. Dresler and K. Sean Kimbro. 2,3-dideoxythymidine 5'triphosphate inhibition of DNA replication and ultraviolet-induced DNA repair synthesis in human cells: evidence for involvement of DNA polymerase delta. Journal of Biochemistry. 26: 2664-2668, 1987.
2. Dean Burkin, K. Sean Kimbro, Barbara L. Barr, Carol Jones, Milton W. Taylor, Sohan L. Gupta. Localization of the human indoleamine 2,3-dioxygenase (IDO) gene to the pericentromeric region of chromosome 8. Genomics 17, 262-263, 1993.
3. B. Azzarelli, R. Woodburn, S. Olivelle, S. Kimbro, A. Siakotos, M. Taylor, CH. Lee, M. Yen, J. Paulsrud. The A-1 antigen: a novel marker in experimental peripheral nerve injury. Journal of Comparative Neurology. 337(3), 353-365, 1993.
4. Raul A. Saavedra, Adam Lipson, K. Sean Kimbro, and Cecilia Ljubetic. The structural complexities of the myelin basic protein gene from mouse are also present in shark. Journal of Molecular Neuroscience, 4(4), 215-223, 1993.
5. K. Sean Kimbro, Paul A. Rosenberg, and Raul A. Saavedra. Box I and II motif from myelin basic protein gene promoter binds to nuclear proteins from rodent brain. Journal of Molecular Neuroscience, 5(1), p. 1-8, 1994.
6. Raul A. Saavedra, K. Sean Kimbro, Doris N. Stern, Jamie Schnuer, Samy Ashkar, Melvin Glimcher and Cecilia I. Ljubetic. Gene expression and phosphorylation of mouse osteopontin. New York Academy of Sciences, 760, 35-43, 1995.
7. Kenneth Korach, John F. Couse, Sylvia W. Curtis, Todd F. Washburn, Jonathan Lindzey, K. Sean Kimbro, Dennis B. Lubahn, Edward M. Eddy, Suzanne M. Snedeker, David W. Schomberg, and Eric P. Smith. Estrogen receptor gene disruption: molecular characterization, experimental and clinical phenotypes. Recent Progress in Hormone Research, 51: 159-86, 1996.
8. Korach, K.S., Taki, M., Kimbro, K.S. "The effects of estrogen receptor gene disruption on bone." Proceedings 2nd International Symposium on Women’s Health and Menopause: Risk Reduction Strategies. Kluwer Academics Publishing, Dordrecht, The Netherlands, 1997.
9. Jose Torron, Cecilia L. Ljubetic, Li Jun Huang, K. Sean Kimbro, Charissa Dyer, and Raul A. Saavedra. A novel motif in the promoter of the myelin basic protein gene binds to nuclear proteins from mouse brain. Journal of Molecular Neuroscience, 8(3): 181-191, 1997.
10. Sharifeh Mehrabi, Udoudo M. Ekanemesang, Felix O. Aikhionbare, K. Sean Kimbro and Judith Bender. Identification and Characterization of Rhodopseudomonas sp., A Purple, Non-Sulfur Bacterium from Microbial Mats. Genetic Analysis: Biomolecular Bioengineering. 18(2): 409-56, 2001.
11. J. David Holtzclaw, Arri Eisen, Erika M. Whitney, Meera Penumetcha,J. Joseph Hoey,‡ and K. Sean Kimbro. Incorporating a New Bioinformatics Component into Genetics at a Historically Black College: Outcomes and Lessons. CBE Life Sci Educ. Spring;5(1):52-64, 2006.
12. Hypoxia-inducible factor-1 in human breast and prostate cancer. K S Kimbro and J W Simons. Endocr Relat Cancer. Sep;13(3):739-49, 2006.
13. Kimbro KS, Duschene K, Willard M, Moore JA, Freeman S. A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment. Molecular Biology Reports, Mar; 35 (1):23-7, 2008.
14. Smith E, Specker B, Bachrach B, Kimbro KS, Li XJ, Young M, Fedarko N, Abuzzhab J, Frand G, Horn J, Kirk P, Cohen RM, Lubahn D, Korach K. Impact on bone of a human estrogen receptor-alpha gene loss of function mutation. The Journal of Clinical Endocrinology & Metabolism. 93(8): 3088-96, 2008.
15. Tisheeka R. Graham, Haiyen E. Zhau, Valerie A. Odero-Marah, Adeboye O. Osunkoya, K. Sean Kimbro, Mourad Tighiouart, Tongrui Liu, Jonathan W. Simons and Ruth M. O’Regan.IGF-I Dependent Upregulation of ZEB1 Expression Drives EMT in human prostate cancer cells in vitro. Cancer Res.; 68:2479-2488, April 2008.
16. Kevin Kimbro and Sabrenia Parker. Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer. Recent Patents on Anti-Cancer Drug Discovery. 2009 Nov;4(3):189-95. PMID:19522696
17. Jackson KA, Oprea G, Handy J, Kimbro KS. Estrogen regulation of STYK1 expression in estrogen receptor-alpha negative ovarian cancer cell lines. J Ovarian Res. Oct 21;2(1):15, 2009
18. Graham TR, Yacoub R, Taliaferro-Smith L, Osunkoya AO, Odero-Marah VA, Liu T, Kimbro KS, Sharma D, O'Regan RM, Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells. Breast Cancer Res Treat. Nov 18, 2009.
19. Lavender NA, Rogers EN, Yeyeodu S, Rudd J, Hu T, Zhang J, Brock GN, Kimbro KS, Moore JH, Hein DW, Kidd LC. Interaction among apoptosis-associated sequence variants and joint effects on aggressive prostate cancer. BMC Med Genomics. 2012 Apr 30;5-11.
20. Kidd LR, Jones DZ, Rogers EN, Kidd NC, Beache S, Rudd JE, Ragin C, Jackson M, McFarlane-Anderson N, Tulloch-Reid M, Morrison S, Brock GN, Barve SS, Kimbro KS. Chemokine Ligand 5 (CCL5) and chemokine receptor (CCR5) genetic variants and prostate cancer risk among men of African Descent: a case-control study. Hered Cancer Clin Pract. 2012 Nov 20; 10(1):16.
21. E N Rogers, D Z Jones, N C Kidd, S Yeyeodu, G Brock, C Ragin, M Jackson, N McFarlane-Anderson, M Tulloch-Reid, K Sean Kimbro, L R Kidd. Toll-like receptor-associated sequence variants and prostate cancer risk among men of African descent. Genes Immunity, epub. May 9, 2013; PMID:23657238
22. Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment. Kidd LR, Roger EN, Yeyeodu ST, Jones DZ, Kimbro KS. Breast Cancer: Targets and Therapy 2013(5):43-51
23. Susan T. Yeyeodu, La Creis R. Kidd, G.M. Oprea, Tiva T. Vancleave, J.Y. Shim, Kevin S. Kimbro. IRAK4 and TLR3 Sequence Variants may Alter Breast Cancer Risk among African-American Women. Frontiers in Immunology 2013(4):338. (Impact factor 6.4, 2019)
24. Dominique Z Jones, Camille Ragin, Nayla C Kidd, Rafael E Flores-Obando, Maria Jackson, Norma McFarlane-Anderson, Marshall Tulloch-Reid, Kevin S Kimbro and LaCreis R Kidd. The Impact of Genetic Variants in Inflammatory-related Genes on Prostate Cancer Risk among men of African Descent: a case control study. Hereditary Cancer in Clinical Practice 2013, 11(1):19.
25. Dubey B, Jackson M, Zeigler-Johnson C, Devarajan K, Flores-Obando RE, McFarlane-Anderson N, Tulloch-Reid M, Aiken W, Kimbro K, Jones D, Kidd LR, Ragin C. Inflammation polymorphisms and prostate cancer risk in Jamaican men: Role of obesity/body size. Gene. 2017 Sep 10. pii: S0378-1119(17)30724-2.
26. Hooker SE Jr, Woods-Burnham L, Bathina M, Lloyd S, Gorjala P, Mitra R, Nonn L, Kimbro KS, Kittles RA. (shared last author) Genetic Ancestry Analysis Reveals Misclassification of Commonly Used Cancer Cell Lines. Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1003-1009. PMID: 30787054
27. Williams A, Dougal DM, Jenkins W, Greene N, Williams-DeVane C, Kimbro KS. Serum miR-17 levels are downregulated in obese, African American women with elevated HbA1c. J Diabetes Metab Disord. 2019 May 9;18(1):173-179. PMID: 31275888
28. (Hypothesis Paper) S.T. Yeyeodu, L. R. Kidd, and K. Kimbro. Protective Innate Immune Variants in Racial/Ethnic Disparities of Breast and Prostate Cancer. Cancer Immunology Research 2019, 7(9):1384-1389
29. Reed DZ, Krupp N, Suman S, Yeyeodu S, Kimbro KS, et al. An Evaluation of Innate Immune Anomalies in Colorectal Tumorigenesis and Precision Medicine. J Cancer Sci Ther. 2019, 11: 213-223.
30. Ariel Williams, Natasha Greene, K. Sean Kimbro. Increased Circulating Cytokines Levels in African American women with Obesity and Elevated HbA1c. Cytokine, April 2020; 128: 154989.
31. Bhawna Dubey, Maria Jackson, Charnita Zeigler-Johnson, Karthik Devarajan, Rafael E Flores-Obando, Norma McFarlane-Anderson, Marshall Tulloch-Reid, William Aiken, Kevin Kimbro, Dominique Jones, LaCreis R. Kidd, Denise Gibbs, Sudhir Kumar, Camille Ragin. Interactive effect of TLR SNPs and exposure to sexually transmitted infections on Prostate cancer risk in Jamaican men. Prostate, 2020, Nov;80(15):1365-1372.
32. Taylor LC, Watkins CS, Chesterton H, Kimbro KS, Gerald R. Rural Community Engagement for Health Disparities Research: The Unique Role of Historically Black Colleges and Universities (HBCUs). Int J Environ Res Public Health. 2020 Dec 23;18(1):64.
33. Doherty IA, Pilkington W, Brown L, Billings V, Hoffler U, Paulin L, Kimbro KS, Baker B, Zhang T, Locklear T, Robinson S, Kumar D. COVID-19 Vaccine Hesitancy in Underserved Communities of North Carolina. medRxiv. 2021 Feb 23:2021.02.21.21252163. (PMCID: PMC7924290)
34. Henry Akintobi T, Sheikhattari P, Shaffer E, Evans CL, Braun KL, Sy AU, Mancera B, Campa A, Miller ST, Sarpong D, Holliday R, Jimenez-Chavez J, Khan S, Hinton C, Sellars-Bates K, Ajewole V, Teufel-Shone NI, McMullin J, Suther S, Kimbro KS, Taylor L, Velez Vega CM, Williams C, Perry G, Zuchner S, Marzan Rodriguez M, Tchounwou PB.Int J Community Engagement Practices at Research Centers in U.S. Minority Institutions: Priority Populations and Innovative Approaches to Advancing Health Disparities Research. Environ Res Public Health. 2021 Jun 21;18(12):6675.
Kevin Sean Kimbro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
Provided by https://patents.justia.com/inventor/
|Genetic Determinants of Prostate and Breast Cancer Risk|
|Abstract||Described are methods of determining if a subject has a genetic predisposition to developing prostate cancer (PCa) or aggressive PCa, or to developing breast cancer (BrCa).|
|Filed||March 30, 2012|
|Date of Patent||January 30, 2018|
|Assignees||North Carolina Central University, University of Louisville Research Foundation, Inc.|
|Inventors||La Creis Renee Kidd, Kevin Sean Kimbro|
|Genetic Determinants of Prostate Cancer Risk|
|Abstract||Described are methods of determining if a subject has a genetic predisposition to developing prostate cancer (PCa), e.g., an American or Caribbean subject of African descent, and of reducing their risk.|
|Filed||May 31, 2013|
|Date of Patent||January 9, 2018|
|Assignees||North Carolina Central University, University of Louisville Research Foundation|
|Inventors||La Creis Renee Kidd, Kevin Sean Kimbro|